Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Activated Protein C
27%
Activated Prothrombin Complex Concentrates (aPCC)
11%
Aflibercept
16%
Basic Fibroblast Growth Factor (bFGF)
11%
Bevacizumab
14%
Bleeding
32%
Bleeding Episodes
12%
Bypassing Agents
13%
Clot Formation
20%
Conjunctival
13%
Corneal Neovascularization
22%
Emicizumab
46%
Factor VII Deficiency
11%
Factor VIII (FVIII)
10%
Factor XI Deficiency
16%
FEIBA
26%
Fibrinogen
16%
Fibrinolysis
24%
Glanzmann Thrombasthenia
22%
Growth Inhibition
11%
Haemophilia with Inhibitors
10%
Hemophilia
61%
Hemophilia B
19%
Hemophilia Patients
21%
High-responding Inhibitors
11%
Human Breast Cancer Cells
11%
Major Surgery
12%
MCF-7
12%
Murine Model
13%
Myopic Choroidal Neovascularization (mCNV)
13%
NLRP3 Inflammasome
11%
Patients with Haemophilia
24%
Platelets
12%
Rabbit Model
23%
Rare Bleeding Disorders
13%
Rat Model
22%
Recombinant Activated Factor VII (rFVIIa)
61%
Retina
26%
Riboflavin
16%
Rotational Thromboelastometry (ROTEM)
24%
Scleral Crosslinking
11%
Severe Haemophilia A
17%
Surgical Procedures
10%
Thrombin Generation
100%
Thrombin Generation Assay
14%
Thrombin-activatable Fibrinolysis Inhibitor
11%
Tissue Factor
17%
Tissue Plasminogen Activator (t-PA)
20%
Ultraviolet Radiation
11%
World Data
18%
Pharmacology, Toxicology and Pharmaceutical Science
Activated Protein C
21%
Activated Prothrombin Complex
12%
Aflibercept
16%
Antifibrinolytic Agent
5%
Antithrombin
7%
Bevacizumab
17%
Bleeding
29%
Bleeding Disorder
17%
Blood Clotting Factor
8%
Blood Clotting Factor 11
23%
Blood Clotting Factor 7
23%
Blood Clotting Factor 7 Deficiency
9%
Blood Clotting Factor 8
11%
Blood Clotting Factor 8 Inhibitor
9%
Blood Stasis
20%
Breast Cancer
11%
Chemical Burn
6%
Ciclonicate
10%
Clotting Time
6%
Cornea Neovascularization
22%
Diseases
7%
Emicizumab
45%
Fibrinolytic Agent
9%
Fibroblast Growth Factor 2
6%
Glanzmann Disease
5%
Haemophilia A
77%
Haemophilia B
10%
Histone Deacetylase Inhibitor
11%
Inflammation
11%
Interleukin 1
5%
Interleukin 6
5%
Leporidae
9%
Messenger RNA
5%
Mouse Model
11%
Proliferative Diabetic Retinopathy
7%
Protein C
6%
Rabbit Model
6%
Rat Model
22%
Recombinant Blood Clotting Factor 7a
31%
Replacement Therapy
9%
Retina Detachment
10%
Retina Disease
12%
Subretinal Neovascularization
19%
Thrombin
76%
Thromboplastin
8%
Tissue Factor Pathway Inhibitor
8%
Tissue Plasminogen Activator
16%
Tranexamic Acid
8%
Vasculotropin
13%
Visual Pigment
11%
Medicine and Dentistry
Activated Prothrombin Complex
12%
Angiogenesis
6%
Antifibrinolytic
6%
Bevacizumab
6%
Bleeding
36%
Bleeding Diathesis
10%
Bleeding Disorder
21%
Blood Clotting Factor 8
7%
Blood Clotting Factor 8 Inhibitor
8%
Blood Stasis
17%
Choroidal Neovascularization
11%
Ciclonicate
7%
Corneal Neovascularization
11%
Cross-Link
16%
D-Dimer
6%
Diseases
11%
Emicizumab
33%
Endothelial Cell
9%
Ex Vivo
11%
Factor XI
22%
Glanzmann's Thrombasthenia
16%
Haemophilia A
61%
Haemophilia B
11%
Hemostat
20%
Histone Deacetylase Inhibitor
11%
Immunological Tolerance
8%
In Vitro
7%
Marstacimab
5%
Microparticle
5%
Myopia
11%
Patient with Hemophilia
22%
Pediatrics
6%
Platelet
7%
Proliferative Diabetic Retinopathy
7%
Prospective Study
6%
Real-World Data
7%
Recombinant Blood Clotting Factor 7a
11%
Retina Disease
11%
Retinal Detachment
16%
Riboflavin
16%
Substitution Therapy
8%
Surgical Technique
9%
Thrombin
54%
Thrombocytopenia
6%
Thromboelastography
7%
Thromboelastometry
7%
Thrombosis
12%
Tissue Factor Pathway Inhibitor
6%
Treatment Option
7%
Vitreous
5%
